Acumen Pharmaceuticals Inc. develops therapies for the treatment of Alzheimer's disease. Acumen's approach targets AbOs, a toxic and pathogenic form of Ab relative to Ab monomers and amyloid plaques. The company's lead immunotherapy drug candidate ACU193, is a humanized monoclonal antibody that is in Phase I clinical-stage trials. Acumen Pharmaceuticals was incorporated in 1996 and is headquartered in Charlottesville, VA.
Name / Ticker | Price | Zen Rating |
---|---|---|
$1.72 | A | |
$44.23 | A | |
$8.00 | A |